Accessibility Menu
Aspen Pharmacare logo

Aspen Pharmacare(OTC) APNHY

Market Cap$4.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)+70%
5 Year-15%
1 Year+51%
1 Month+5%
$9.41
+0.00%
+0.00Today
Aspen Pharmacare last closing stock price
MetricPriceDate
Last closeUSD 9.412026-08-13
Aspen Pharmacare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.93%USD 8.892026-08-06
1 month+4.57%USD 9.002026-07-14
3 month+6.77%USD 8.822026-05-15
Year to date+42.93%USD 6.582025-12-31
1 year+51.15%USD 6.232025-08-13
3 year-0.17%USD 9.432023-08-14
5 year-14.96%USD 11.072021-08-13
Since inception+69.64%USD 5.552009-06-05

Aspen Pharmacare Financials at a Glance

Market Cap

$4.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

ZAR 83.20B

Net Income (TTM)

ZAR 2.41B

EPS (TTM)

-$0.23

P/E Ratio

-40.12

Dividend

$0.12

Beta (Volatility)

0.35 (Low)

Price

$9.41

Volume

2

Open

$9.41

Previous Close

$9.41

Daily Range

$9.41 - $9.41

52-Week Range

$5.24 - $9.45

Estimated Earnings Date

Sep 2, 2026

APNHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aspen Pharmacare

Aspen Pharmacare Holdings Limited is a leading global pharmaceutical company that specializes in manufacturing and marketing branded and specialty pharmaceutical products. The company operates across various regions, including Africa, the Middle East, the Americas, Europe, and Asia, focusing on therapeutic areas such as anaesthetics, anticoagulants, and analgesics.

Products and Services
  • Injectables for therapeutic areas including anaesthetics and anticoagulants
  • Over-the-counter medicines for various health conditions
  • Prescription products for anti-inflammatories and immunosuppressants
Growth Outlook
  • Recent quarterly revenue reached ZAR 16.27 billion, indicating strong market demand
  • Gross profit margin improved to 43.6% in the latest quarter
  • Expansion into new markets is expected to drive future growth
Financial Highlights
  • Trailing twelve months revenue of ZAR 21.14 billion, showcasing consistent performance
  • Net income of ZAR 2.31 billion in the latest quarter, reflecting operational efficiency
  • Current ratio of 3.64 indicates strong liquidity position
Aspen Pharmacare Holdings Limited has established itself as a significant player in the pharmaceutical industry, with a diverse portfolio of products catering to various therapeutic needs. The company's focus on innovation and expansion into new markets positions it well for future growth. Recent financial performance highlights a robust revenue stream and improving profitability, making it an attractive option for potential investors. The strong liquidity position further enhances its ability to navigate market challenges and capitalize on new opportunities.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,557

CEO

Stephen Bradley Saad, PhD

Website

www.aspenpharma.com

Headquarters

Durban, NL 2191, ZA

APNHY Financials

Key Financial Metrics (TTM)

Gross Margin

41.91%

Operating Margin

16.01%

Net Income Margin

-5.19%

Return on Equity

-2.41%

Return on Capital

1.19%

Return on Assets

-1.56%

Earnings Yield

-2.49%

Dividend Yield

1.30%

Payout Ratio

-47.07%

Stock Overview

Market Cap

$4.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

444.02M

Volume

2

Avg. Volume

202.191

Financials (TTM)

Gross Profit

ZAR 36.33B

Operating Income

ZAR 9.52B

EBITDA

ZAR 12.40B

Operating Cash Flow

ZAR 12.33B

Capital Expenditure

-ZAR 5.28B

Free Cash Flow

ZAR 7.06B

Cash & ST Invst.

ZAR 5.61B

Total Debt

ZAR 32.91B

Aspen Pharmacare Performance Analysis

Aspen Pharmacare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30ZAR 2,536,915,177N/A
20232023-06-30ZAR 2,291,231,296-9.7%
20242024-06-30ZAR 2,388,834,3334.3%
20252025-06-30ZAR 2,387,723,936-0.0%
Aspen Pharmacare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3011.5%
Q22024-12-31-6.8%
Q42025-06-30-2.5%
Q22025-12-31-24.0%
Aspen Pharmacare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30ZAR 0.94N/A
20232023-06-30ZAR 0.66-29.6%
20242024-06-30ZAR 0.53-20.0%
20252025-06-30ZAR -0.13N/A
Aspen Pharmacare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-9.6%
Q22024-12-3114.2%
Q42025-06-30-245.4%
Q22025-12-31140.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

ZAR 16.27B

-23.0%

Gross Profit

ZAR 7.10B

-23.8%

Gross Margin

43.64%

N/A

Market Cap

$4.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$437.26K

N/A

Employees

9,557

N/A

Net Income

ZAR 1.40B

-39.4%

EBITDA

ZAR 3.87B

-12.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

ZAR 5.61B

-51.6%

Total Debt

ZAR 32.91B

-8.9%

Accounts Receivable

ZAR 10.07B

+1010.1%

Inventory

ZAR 15.44B

-18.5%

Long Term Debt

ZAR 29.31B

+19.5%

Short Term Debt

ZAR 3.60B

-68.9%

Return on Assets

-1.56%

N/A

Return on Invested Capital

5.49%

N/A

Free Cash Flow

ZAR 2.33B

+141.5%

Operating Cash Flow

ZAR 3.41B

+38.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HYPMYHypera S.A.
$4.11-3.41%
CURLFCuraleaf Holdings, Inc.
$9.32-3.63%
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
CASBFCanSino Biologics Inc.
$3.15+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.06+0.08%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.69+0.01%
ONDSOndas
$9.14+0.03%
SPCXSpace Exploration Technologies
$139.49-0.01%

Questions About APNHY

What is the current price of Aspen Pharmacare?

Aspen Pharmacare is trading at $9.41 per share.

What is the 52-week range for Aspen Pharmacare?

Over the past 52 weeks, Aspen Pharmacare has traded between $5.24 and $9.45.

How much debt does Aspen Pharmacare have?

As of the most recent reporting period, Aspen Pharmacare reported total debt of ZAR 2.03B.

How much cash does Aspen Pharmacare have on hand?

Aspen Pharmacare reported ZAR 360.64M in cash and cash equivalents in its most recent financial results.

What is Aspen Pharmacare’s dividend yield?

Aspen Pharmacare currently has a dividend yield of 1.30%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services